Oral low-dose tacrolimus therapy for refractory hemophagocytic syndrome associated with systemic lupus erythematosus

Modern Rheumatology

Volumn 22, Issue 2, 2012, Pages 284-289

  Watanabe, Hideyuki ^a   Hirase, Nobuhisa ^a   Goda, Hideaki ^a   Nishikawa, Hiroshi ^a   Ikuyama, Shoichiro ^a  

^a KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

Author keywords

Hemophagocytic syndrome; Systemic lupus erythematosus; Tacrolimus

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; PREDNISOLONE; TACROLIMUS;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CASE REPORT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FEVER; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOPATHOLOGY; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MONOTHERAPY; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URTICARIAL VASCULITIS; VASCULITIS;

BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MIDDLE AGED; PANCYTOPENIA; PREDNISOLONE; REMISSION INDUCTION; TACROLIMUS; TREATMENT FAILURE; TREATMENT OUTCOME; URTICARIA; VASCULITIS;

EID: 84861478597     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0491-y     Document Type: Article

References (30)

1. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166:95-109. (Pubitemid 46025500)
2. Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6:137-54.
3. Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49:633-9. (Pubitemid 37296468)
4. Wong KF, Hui PK, Chan JK, Chan YW, Ha SY. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991;114:387-90.
5. Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130:1655-63. (Pubitemid 30611945)
6. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562-75. (Pubitemid 350294223)
7. Furukawa Y, Yoshikawa H, Iwasa K, Yamada M. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol. 2008;195:108-15.
8. Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58:990-9.
9. Kitahama M, Okamoto H, Koseki Y, Inoue E, Kaneko H, Taniguchi A, Momohara S, Yamanaka H. Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis. Mod Rheumatol. 2010;20:478-85.
10. Lee T, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Kim S, Chin HJ. Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus. 2010;19:974-80.
11. Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I, Mitoma H, et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010;28:6-12.
12. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129:750-4. (Pubitemid 27498287)
13. Kumakura S, Ishikura H, Kondo M, Murakawa Y, Masuda J, Kobayashi S. Autoimmune-associated hemophagocytic syndrome. Mod Rheumatol. 2004;14:205-15. (Pubitemid 39206664)
14. Hide M, Furue M, Ikezawa Z, Shiohara T, Furukawa F, Matsunaga K, et al. Guidelines for the diagnosis and treatment of urticaria and angioedema. Jpn J Dermatol. 2005;115:703-15.
15. Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford). 2009;48:691-5.
16. Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med. 2006;38:20-31. (Pubitemid 43177784)
17. Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford). 2008;47:1686-91.
18. Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89:4100-3. (Pubitemid 27220957)
19. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest. 1997;100:1969-79. (Pubitemid 27459350)
20. Kumakura S, Ishikura H, Endo J, Kobayashi S. Autoimmune-associated hemophagocytosis. Am J Hematol. 1995;50:148-9.
21. Quismorio FP, Jr. Hematologic and lymphoid abnormalities in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 801-28.
22. Kino T, Hatanaka H, Miyata S, et al. FK-506 a novel immuno-suppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot. 1987;40:1256-65. (Pubitemid 17138110)
23. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247-97. (Pubitemid 36750952)
24. Smith DF, Toft DO. Steroid receptors and their associated proteins. Mol Endocrinol. 1993;7:4-11. (Pubitemid 23047199)
25. Masri MA. The mosaic of immunosuppressive drugs. Mol Immunol. 2003;39:1073-7. (Pubitemid 36776559)
26. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1993;46:746-94. (Pubitemid 23331067)
27. Asamiya Y, Uchida K, Otsubo S, Takei T, Nitta K. Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center. Nephron Clin Pract. 2009;113:c330-6
28. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19:606-15.
29. Kusunoki Y, Tanaka N, Kaneko K, Yamamoto T, Endo H, Kawai S. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. Mod Rheumatol. 2009;19:616-21.
30. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2008;67:380-8. (Pubitemid 351281275)